Intestinal and oral mucosal cells

Intestinal and oral mucosal cells constitute the epithelial lining of the gastrointestinal tract and oral cavity, serving as a critical barrier between the internal environment and external pathogens or toxins (StatPearls, 2023). These cells, including enterocytes and squamous epithelial cells, are characterized by a high rate of turnover, making them particularly susceptible to the cytotoxic effects of chemotherapy and radiation therapy (Sonis, 2004). This susceptibility often results in oral and intestinal mucositis, a significant dose-limiting toxicity in oncology that manifests as painful ulceration and impaired barrier function (NIH, 2023). While not a single molecular target, these cells are the site of action for cytoprotective agents like Palifermin, which targets the FGFR2b receptor to promote epithelial repair (PubChem, 2024). Furthermore, the health of these cells is vital for the absorption of oral therapeutics and the prevention of systemic translocation of gut bacteria (PubMed, 2022). Understanding the physiology and regenerative capacity of these mucosal populations is essential for developing strategies to mitigate treatment-induced toxicities and manage inflammatory conditions like IBD.

Other names

Mucosal epitheliumGastrointestinal epithelial cellsOral epithelial cellsEnterocytesIntestinal epithelium

Cytotoxic drugs like 5-Fluorouracil inhibit DNA synthesis and thymidylate synthase in these rapidly dividing cells, leading to mucosal atrophy and ulceration (PubChem). Cytoprotective agents like Palifermin act as agonists at the fibroblast growth factor receptor 2b (FGFR2b) to stimulate epithelial cell proliferation, differentiation, and survival (FDA).